CytomX Therapeutics (STU:6C1) Cyclically Adjusted FCF per Share: €-0.76 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6C1 CytomX Therapeutics Inc STU:6C1
42 GF Score
Price €2.75
GF Value €0.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is CytomX Therapeutics Cyclically Adjusted FCF per Share?

CytomX Therapeutics STU:6C1 -2.45% 42 Cyclically Adjusted FCF per Share is €-0.76 as of Jun. 2026. GuruFocus rates STU:6C1 with a GF Score™ of 42/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CytomX Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.072. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.76 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-15), CytomX Therapeutics's current stock price is €2.749. CytomX Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.76. CytomX Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


CytomX Therapeutics  (STU:6C1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CytomX Therapeutics Cyclically Adjusted FCF per Share Related Terms


CytomX Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Cyclically Adjusted FCF per Share Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.70 -0.77 -0.97 -0.63

CytomX Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.64 -0.70 -0.68 -0.69 -0.76

STU:6C1 vs GYRE, BBOT, TECX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:6C1
42GF Score
CytomX Therapeutics Inc STU:6C1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytomX Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.072/333.9520*333.9520
=-0.072

Current CPI (Jun. 2026) = 333.9520.

CytomX Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.368 241.428 -0.509
201612 0.029 241.432 0.040
201703 -0.514 243.801 -0.704
201706 4.287 244.955 5.845
201709 -0.368 246.819 -0.498
201712 0.470 246.524 0.637
201803 -0.323 249.554 -0.432
201806 -0.602 251.989 -0.798
201809 -0.149 252.439 -0.197
201812 -0.599 251.233 -0.796
201903 -0.798 254.202 -1.048
201906 -0.970 256.143 -1.265
201909 -0.493 256.759 -0.641
201912 -0.609 256.974 -0.791
202003 -0.980 258.115 -1.268
202006 1.913 257.797 2.478
202009 -0.524 260.280 -0.672
202012 -0.331 260.474 -0.424
202103 -0.421 264.877 -0.531
202106 -0.361 271.696 -0.444
202109 -0.406 274.310 -0.494
202112 -0.457 278.802 -0.547
202203 -0.573 287.504 -0.666
202206 -0.526 296.311 -0.593
202209 -0.579 296.808 -0.651
202212 -0.004 296.797 -0.005
202303 0.131 301.836 0.145
202306 -0.357 305.109 -0.391
202309 -0.207 307.789 -0.225
202312 -0.313 306.746 -0.341
202403 -0.292 312.332 -0.312
202406 -0.217 314.175 -0.231
202409 -0.212 315.301 -0.225
202412 -0.257 315.605 -0.272
202503 -0.231 319.799 -0.241
202506 -0.097 322.561 -0.100
202509 -0.074 324.800 -0.076
202512 -0.119 324.054 -0.123
202603 -0.123 330.213 -0.124
202606 -0.072 333.952 -0.072

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.76 mean?
CytomX Therapeutics (STU:6C1) has a Cyclically Adjusted FCF per Share of €-0.76 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Cyclically Adjusted FCF per Share too high?
CytomX Therapeutics' current Cyclically Adjusted FCF per Share is €-0.76. Overall, CytomX Therapeutics has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Cyclically Adjusted FCF per Share compare to GYRE and BBOT?
CytomX Therapeutics' Cyclically Adjusted FCF per Share of €-0.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Cyclically Adjusted FCF per Share is €-0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (STU:6C1) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €2.75 — trading 2014.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.76. CytomX Therapeutics' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For CytomX Therapeutics (STU:6C1), the current Cyclically Adjusted FCF per Share is €-0.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (STU:6C1) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of €2.75 is trading 2014.6% above its estimated GF Value™ of €0.13. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:6C1:

  • Cyclically Adjusted FCF per Share: €-0.76
  • GF Value™: €0.13 vs. price of €2.75 (2014.6% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the STU:6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges CTMX:USA
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
42GF Score

Get the complete analysis for STU:6C1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.75
Price
€0.13
GF Value